Neumora Therapeutics, Inc. Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Neumora Therapeutics, Inc. Common Stock generated cash of -$163,278,000, which is less than the previous year. Cash used in financing activities reached the amount of $231,936,000 last year. Net change in cash is therefore $133,045,000.
Cash Flow
| 2020 | -26.76M | -11.23M | 230.09M |
|---|---|---|---|
| 2021 | -75.42M | -817K | 293.50M |
| 2022 | -114.89M | -168.01M | 115.74M |
| 2023 | -163.27M | 64.38M | 231.93M |
NMRA Cash Flow Statement (2020 – 2023)
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
Cash at beginning of period | 242.20M | 409.37M | 192.10M | 0 |
Operating activities | ||||
Net income | -235.92M | -130.90M | -237.31M | -99.27M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||
Depreciation and amortization | 668K | 594K | 538K | 105K |
Stock-based compensation expense | 17.24M | 8.29M | 4.27M | 1.67M |
| Deferred income tax benefit | 17.24M | 8.29M | 4.27M | 1.67M |
| Changes in operating assets and liabilities: | ||||
Accounts receivable, net | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 |
Accounts payable | -581K | -1.24M | -759K | -4.67M |
Cash generated by operating activities | -163.27M | -114.89M | -75.42M | -26.76M |
Investing activities | ||||
Purchases Of Investments | -109.07M | -226.36M | 0 | 0 |
Investments In Property Plant And Equipment | -117K | -511K | -817K | -1.3M |
Acquisitions Net | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 64.38M | -168.01M | -817K | -11.23M |
Financing activities | ||||
Common Stock Issued | 233.37M | 115.74M | 960K | 3.19M |
Payments for dividends | 0 | 0 | 0 | 0 |
Repurchases of common stock | -491K | 0 | 0 | -2K |
Repayments of term debt | 0 | 0 | 0 | -55.90M |
Cash used in financing activities | 231.93M | 115.74M | 293.50M | 230.09M |
Net Change In Cash | 133.04M | -167.16M | 217.27M | 192.10M |
Cash at end of period | 375.25M | 242.20M | 409.37M | 192.10M |
| Data source |